<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01304121</url>
  </required_header>
  <id_info>
    <org_study_id>VSSHP#2701/2007</org_study_id>
    <nct_id>NCT01304121</nct_id>
  </id_info>
  <brief_title>Bioactive Glass Granules in Filling of Bone Defects</brief_title>
  <official_title>Bioactive Glass Granules as Bone Graft Substitute in Filling Material of Bone Defects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized clinical trial that will be carried out to examine the use of bioactive
      glass granules (S53P4) as bone graft substitute in filling small and large bone defects as
      compared with autogenous and allogeneic bone grafting, respectively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This a single center randomized trial. The hypothesis of the study is that the selected
      synthetic bone graft (bioactive glass granules, S53P4, Vivoxid Ltd, Turku, Finland) is as
      good as traditional autogenous or allogeneic bone grating in filling of non-traumatic bone
      defects. A total of 48 patients (stratified into two groups) will be included. The underlying
      bone disease will include common bening and semi-malign bone tumors (such as enchondroma and
      giant cell tumors) as well as tumor-like conditions (such as fibrous dysplasia, fibrous
      cortical defect, solitary bone cysts, aneurysmatic bone cyst).

      Group I (n=24) will include patients with small benign bone lesions amenable to evacuation
      and autogenous bone grafting as standard of care. The patients will be randomized to
      autogenous bone grafting or bioactive glass granule filling. The follow-up examinations up to
      52 weeks will include plain X-rays at 4, 26, and 52 weeks as well as MRI ad 4 and 52 weeks.

      Group II (n=24) will include patients with a large bone defect. As the selection criteria,
      large defects have been defined to be defects which need allogeneic bone grafting. The
      patients will be randomized to allogeneic bone grafting or bioactive glass granule filling.
      The patients will be followed up to 52 weeks. The follow-up examinations will include X-rays
      at 4, 26 and 52 weeks as well as PET/CT imaging and MRI at 4 weeks and 52 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiological healing</measure>
    <time_frame>52 weeks</time_frame>
    <description>The healing of bone defects will be examined by plain X-rays and MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical recovery</measure>
    <time_frame>52 weeks</time_frame>
    <description>The outcome of the surgical procedure (i.e. the subjective recovery of the patients) will be evaluated by means of Rand-36 scoring system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PET imaging</measure>
    <time_frame>52 weeks</time_frame>
    <description>PET imaging will be applied to measure blood flow and metabolic activity at the surgical site</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Bone Tumors</condition>
  <arm_group>
    <arm_group_label>Bioactive glass</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resorbable bioactive glass granules</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bioactive glass (SP53P4)</intervention_name>
    <description>Commercial resorbable bone graft substitute (Vioxid Ltd)</description>
    <arm_group_label>Bioactive glass</arm_group_label>
    <other_name>Abmin (trademark), Vioxid Ltd</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  benign bone tumor or tumor-like condition

          -  age 18 years or more

          -  signed informed consent

        Exclusion Criteria:

          -  a history of malignancy

          -  a medication affecting bone metabolism

          -  any device (such as pace maker) as contraindication for MRI imaging

          -  gravidity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hannu T Aro, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>http://www.orthopaedics.utu.fi</url>
    <description>Homepage of the clinical research unit</description>
  </link>
  <reference>
    <citation>Välimäki VV, Aro HT. Molecular basis for action of bioactive glasses as bone graft substitute. Scand J Surg. 2006;95(2):95-102. Review.</citation>
    <PMID>16821652</PMID>
  </reference>
  <reference>
    <citation>Välimäki VV, Moritz N, Yrjans JJ, Vuorio E, Aro HT. Effect of zoledronic acid on incorporation of a bioceramic bone graft substitute. Bone. 2006 Mar;38(3):432-43. Epub 2005 Dec 9.</citation>
    <PMID>16338190</PMID>
  </reference>
  <reference>
    <citation>Keränen P, Itälä A, Koort J, Kohonen I, Dalstra M, Kommonen B, Aro HT. Bioactive glass granules as extender of autogenous bone grafting in cementless intercalary implant of the canine femur. Scand J Surg. 2007;96(3):243-51.</citation>
    <PMID>17966751</PMID>
  </reference>
  <reference>
    <citation>Zhao D, Moritz N, Vedel E, Hupa L, Aro HT. Mechanical verification of soft-tissue attachment on bioactive glasses and titanium implants. Acta Biomater. 2008 Jul;4(4):1118-22. doi: 10.1016/j.actbio.2008.02.012. Epub 2008 Mar 4.</citation>
    <PMID>18356122</PMID>
  </reference>
  <reference>
    <citation>Koort JK, Suokas E, Veiranto M, Mäkinen TJ, Jalava J, Törmälä P, Aro HT. In vitro and in vivo testing of bioabsorbable antibiotic containing bone filler for osteomyelitis treatment. J Biomed Mater Res A. 2006 Sep 1;78(3):532-40.</citation>
    <PMID>16736479</PMID>
  </reference>
  <reference>
    <citation>Alm JJ, Frantzén JP, Moritz N, Lankinen P, Tukiainen M, Kellomäki M, Aro HT. In vivo testing of a biodegradable woven fabric made of bioactive glass fibers and PLGA80--a pilot study in the rabbit. J Biomed Mater Res B Appl Biomater. 2010 May;93(2):573-80. doi: 10.1002/jbm.b.31618.</citation>
    <PMID>20229522</PMID>
  </reference>
  <reference>
    <citation>Keränen P, Koort J, Itälä A, Ylänen H, Dalstra M, Hupa M, Kommonen B, Aro HT. Bioceramic inlays do not improve mechanical incorporation of grit-blasted titanium stems in the proximal sheep femur. J Biomed Mater Res A. 2010 Mar 15;92(4):1578-86. doi: 10.1002/jbm.a.32494.</citation>
    <PMID>19437438</PMID>
  </reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2011</study_first_submitted>
  <study_first_submitted_qc>February 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2011</study_first_posted>
  <last_update_submitted>June 15, 2011</last_update_submitted>
  <last_update_submitted_qc>June 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Hannu T Aro</name_title>
    <organization>Turku University Hospital</organization>
  </responsible_party>
  <keyword>Bone tumors</keyword>
  <keyword>Bioactive glass</keyword>
  <keyword>Autogenous bone grafting</keyword>
  <keyword>Allogeneic bone grafting</keyword>
  <keyword>PET imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

